AbCellera Biologics Inc (ABCL)
3.78
+0.08
(+2.16%)
USD |
NASDAQ |
May 16, 16:00
3.79
+0.01
(+0.26%)
After-Hours: 20:00
AbCellera Biologics Revenue (Quarterly): 9.954M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 9.954M |
| December 31, 2023 | 9.179M |
| September 30, 2023 | 6.599M |
| June 30, 2023 | 10.06M |
| March 31, 2023 | 12.19M |
| December 31, 2022 | 21.54M |
| September 30, 2022 | 101.38M |
| June 30, 2022 | 45.92M |
| March 31, 2022 | 316.58M |
| Date | Value |
|---|---|
| December 31, 2021 | 139.33M |
| September 30, 2021 | 5.508M |
| June 30, 2021 | 27.64M |
| March 31, 2021 | 202.74M |
| December 31, 2020 | 207.91M |
| September 30, 2020 | 9.362M |
| June 30, 2020 | 11.23M |
| March 31, 2020 | 4.657M |
| December 31, 2019 | 3.203M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
3.203M
Minimum
Dec 2019
316.58M
Maximum
Mar 2022
63.61M
Average
11.71M
Median
Revenue (Quarterly) Benchmarks
| Acasti Pharma Inc | -- |
| Aurinia Pharmaceuticals Inc | 45.10M |
| Edesa Biotech Inc | -- |
| Lexaria Bioscience Corp | 0.145M |
| InMed Pharmaceuticals Inc | 1.240M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -40.61M |
| Total Expenses (Quarterly) | 61.57M |
| EPS Diluted (Quarterly) | -0.14 |
| Enterprise Value | 413.50M |
| Profit Margin (Quarterly) | -408.0% |
| Earnings Yield | -13.76% |
| Normalized Earnings Yield | -13.76 |